SSII heads into the post-earnings session with its thesis intact: a group of high-conviction insiders bought $5.2M of stock at depressed levels in March, shorts have been unwinding steadily ever since, and the Q1 numbers released today show exactly why.
Revenue more than doubled year-on-year to $11.1M in Q1 2026. Loss per share narrowed from $(0.03) to $(0.02). Neither figure screams profitability, but the trajectory is clear — and the insiders who stepped in at $3.99–$4.01 in early March were buying that trajectory, not the current income statement.
The insider cluster in March was the standout signal for this stock. CEO and Chairman Sudhir Srivastava bought ~499K shares for $2.0M. Executive Vice Chairman Frederic Moll added ~501K shares for another $2.0M. Director Timothy Adams put in $1.2M for 300K shares. All three bought on the same day, March 6, at essentially the same price — roughly 8% below where the stock trades today. That kind of coordinated buying at this scale is unusual for a company with a market cap this size and makes a statement about management's read on near-term milestones.
The short-interest picture reinforces that read. Shorts have been a diminishing force since early April, when estimated SI peaked around 0.53% of the free float and the lending market briefly tightened to the point of fully using all available shares. Since then, short positions have been cut by more than 75%. SI now sits at just 0.13% of float — low enough that the short side of the trade is no longer a meaningful driver of price action. What remains more interesting is the borrow cost: despite the collapse in short interest, cost to borrow is running at 33.5%, up 5% on the week. That's elevated for a stock with this little short positioning. It points to a tight, thinly supplied lending pool — availability is narrow even though few are actually borrowing. The 52-week peak on availability utilization was 100%, hit briefly on April 9. Today's reading of 60% is more comfortable, but the borrow market hasn't fully loosened.
There are two structural developments worth watching alongside the earnings print. First, SS Innovations filed a $150M shelf registration on May 1 — a significant move for a sub-$1B company. The shelf doesn't mean dilution is imminent, but it signals the company is positioning to raise capital, and the timing alongside strong revenue growth and insider buying suggests management sees a use case. Second, the company demonstrated long-distance telesurgery capabilities at the Royal Australian College of Surgeons congress on May 7 and surpassed 10,500 surgeries on its SSi Mantra robotic platform on May 5. Commercial momentum is building.
Peers in the small-cap med-tech space had a mixed week. TNON led the group, up nearly 10% on the week, while HSDT fell close to 3% and AEMD dropped over 7%. SSII's 5.4% weekly gain placed it at the stronger end of the peer range — in line with the stock's improving fundamental backdrop rather than speculative momentum.
The short score, at 57.7, has drifted modestly lower over the past two weeks from a recent high near 58.5 — consistent with the unwinding short interest rather than any fresh build. Factor scores place SSII in the 15th percentile on short score rank and the 6th percentile on days-to-cover, both reflecting how little short pressure remains. What the data cannot yet show is how the market will digest a $150M shelf alongside an improving but still loss-making P&L. That tension — growth momentum versus dilution overhang — is the axis the next few sessions will trade on.
See the live data behind this article on ORTEX.
Open SSII on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
